Multidrug resistance inHelicobacter pylori: current state and future directions

Boyanova, Lyudmila; Hadzhiyski, Petyo; Kandilarov, Nayden; Markovska, Rumyana; Mitov, Ivan

doi:10.1080/17512433.2019.1654858

Cited by 88 publications

(74 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…By comparing our results to this newest meta-analysis, we found that the rate of double resistance (clarithromycin and metronidazole) in this study was lower than Eastern Mediterranean region (14%), European region (15%), and Western Pacific region (11%); on the other hand, it was higher than that in the Americas region (3%) and Southeast Asia region (6%) [51]. It is important to note that multidrug resistance in H. pylori (resistance to ≥3 antibiotics of differ-ent classes) is already an alarming reality in many countries worldwide [60]. This fact generates a worldwide call to pay attention to antibiotic resistance surveillance.…”

Section: Discussioncontrasting

confidence: 48%

Surveillance of the Antimicrobial Resistance Rates of Helicobacter pylori Ten Years Later in the Western Central Region, Colombia

Bedoya-Gómez

Aldana

Moncayo

et al. 2019

Dig Dis

View full text Add to dashboard Cite

Background: Helicobacter pylori is a bacterium associated with gastroduodenal disease and gastric cancer. Empirical therapy in the treatment of H. pylori infection increases the risk of apparition of antimicrobial drug resistance. In a previous report, in H. pylori clinical isolates, resistance rates to commonly used antimicrobial drugs were as follows: metronidazole 82%, clarithromycin 3.8%, and amoxicillin 1.9%. The aim was to establish the variation of resistance rates and the detection of H. pylori genetic mutations isolated from dyspeptic patients. Methods: Antimicrobial susceptibility profiles were performed by the E-test method for metronidazole, clarithromycin, amoxicillin, and tetracycline in 61 clini-cal isolates. Sequencing was performed to detect mutations associated with resistance to clarithromycin. Results: According to our results, resistance rates found in the 61 isolates were 78.60% for metronidazole and 8.20% for clarithromycin. None of the studied isolates had resistance to tetracycline and amoxicillin. Secondary resistance rates displayed an increase when compared to primary rates for metronidazole (87.50 vs. 77.35%) and for clarithromycin (25.66 vs. 5.66%). Of 5 isolates resistant to clarithromycin, 3 had the A2143G mutation. By comparing the results in this work with previous reports, antimicrobial drug resistance rates did not show major modifications for metronidazole, amoxicillin, and tetracycline during the last 10 years. For clarithromycin, the resistance rate showed a moderate increase; nevertheless, it remains low (< 15%) and this change was not statistically significant. Conclusion: Together, all findings in this work indicate that these antimicrobial drugs can still be used as first line of defense on infected patients living in this region of the country.

show abstract

Section: Discussioncontrasting

confidence: 48%

Surveillance of the Antimicrobial Resistance Rates of Helicobacter pylori Ten Years Later in the Western Central Region, Colombia

Bedoya-Gómez

Aldana

Moncayo

et al. 2019

Dig Dis

View full text Add to dashboard Cite

show abstract

“…Because of this fact, researchers and clinicians around the world recommend that infections produced by H. pylori should always be treated [ 6 , 7 ]. Nowadays, however, an alarmingly high detection of multidrug-resistant (MDR) H. pylori strains is observed [ 8 ]. Factors associated with the appearance of MDR strains include antibiotic abuse, therapeutic failures, and phenotypical mechanisms promoting resistance/tolerance of these bacteria to antimicrobial substances (efflux pumps expression, biofilm formation, or morphological transformation) [ 9 , 10 , 11 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

Synergistic Therapies as a Promising Option for the Treatment of Antibiotic-Resistant Helicobacter pylori

2020

View full text Add to dashboard Cite

Helicobacter pylori is a Gram-negative bacterium responsible for the development of gastric diseases. The issue of spreading antibiotic resistance of H. pylori and its limited therapeutic options is an important topic in modern gastroenterology. This phenomenon is greatly associated with a very narrow range of antibiotics used in standard therapies and, as a consequence, an alarmingly high detection of multidrug-resistant H. pylori strains. For this reason, scientists are increasingly focused on the search for new substances that will not only exhibit antibacterial effect against H. pylori, but also potentiate the activity of antibiotics. The aim of the current review is to present scientific reports showing newly discovered or repurposed compounds with an ability to enhance the antimicrobial activity of classically used antibiotics against H. pylori. To gain a broader context in their future application in therapies of H. pylori infections, their antimicrobial properties, such as minimal inhibitory concentrations and minimal bactericidal concentrations, dose- and time-dependent mode of action, and, if characterized, anti-biofilm and/or in vivo activity are further described. The authors of this review hope that this article will encourage the scientific community to expand research on the important issue of synergistic therapies in the context of combating H. pylori infections.

show abstract

“…H. pylori infection is one of the most common bacterial infections, affecting approximately half of the world population [1,2]. It can cause chronic gastritis, which in turn may be complicated with peptic ulcer disease, lymphoma, and gastric adenocarcinoma [3,4].…”

Section: Introductionmentioning

confidence: 99%

“…The major factor that affects the rates of cure from H. pylori infection is the sufficient inhibition of acid secretion using the anti-secretory agents such as proton pump inhibitors (PPIs) [5,6]. However, the incidence of H. pylori infection and its sufficient eradication using pharmacological therapies are also affected by genetic factors, such as those affecting inflammatory cytokines and variants of the genes encoding drug-metabolizing enzymes and drug transporters [1,7,8].…”

Section: Introductionmentioning

confidence: 99%

The Association between ABCB1 C1236T/C3435T SNPs and H. pylori Infection among Jordanians

Banihani

Khabour

Alzoubi

et al. 2020

Genes

View full text Add to dashboard Cite

Infection with Helicobacter pylori (H. pylori) is very common and affecting about 50% of the worldwide population. Several genetic variations have been implicated in determining the clinical susceptibility to this infection. In the current study, we examined the association between C1236T (rs1045642) and C3435T (rs1045642) single nucleotide polymorphisms (SNPs) in the ABCB1 gene and the prevalence of H. pylori infection among Jordanians. A total of 412 subjects (257 H. pylori-positive cases and 155 H. pylori-negative controls) were recruited and participated in the study, and the genotyping of the ABCB1 gene was performed using RFLP-PCR techniques. A significant association was detected between C1236T and H. pylori infection (p < 0.01). The frequency of CT genotype was significantly higher in the positive cases (40.1%) compared to the controls (21.3%). In addition, the C3435T SNP was weakly associated with H. pylori infection (p = 0.077). Haplotype analysis of C1236T and C3435T SNPs showed that the TT haplotype was present in 22.7% of the positive cases compared to 30.7% of the negative controls (p < 0.05, odds ratio = 0.663, 95% CI: (0.483–0.911)). Consequently, the TT haplotype seems to decrease the risk of H. pylori infection. In conclusion, the current results suggest an association between ABCB1 SNPs and H. pylori infection in the Jordanian population.

show abstract

Multidrug resistance inHelicobacter pylori: current state and future directions

Cited by 88 publications

References 67 publications

Surveillance of the Antimicrobial Resistance Rates of <b><i>Helicobacter pylori</i></b> Ten Years Later in the Western Central Region, Colombia

Surveillance of the Antimicrobial Resistance Rates of <b><i>Helicobacter pylori</i></b> Ten Years Later in the Western Central Region, Colombia

Synergistic Therapies as a Promising Option for the Treatment of Antibiotic-Resistant Helicobacter pylori

The Association between ABCB1 C1236T/C3435T SNPs and H. pylori Infection among Jordanians

Contact Info

Product

Resources

About